{'52WeekChange': 0.51656806,
 'SandP52WeekChange': 0.0644362,
 'address1': '400 Oyster Point Boulevard',
 'address2': 'Suite 221',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 25.75,
 'askSize': 800,
 'averageDailyVolume10Day': 52812,
 'averageVolume': 72800,
 'averageVolume10days': 52812,
 'beta': None,
 'beta3Year': None,
 'bid': 9,
 'bidSize': 800,
 'bookValue': 7.025,
 'category': None,
 'circulatingSupply': None,
 'city': 'South San Francisco',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 26.41,
 'dayLow': 25.5,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -9.151,
 'enterpriseToRevenue': None,
 'enterpriseValue': 349371520,
 'exDividendDate': None,
 'exchange': 'NGM',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 28.171429,
 'fiftyTwoWeekHigh': 36.105,
 'fiftyTwoWeekLow': 8.61,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 6978385,
 'forwardEps': -2.31,
 'forwardPE': -11.095238,
 'fromCurrency': None,
 'fullTimeEmployees': 20,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'heldPercentInsiders': 0.11908,
 'heldPercentInstitutions': 0.77851,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/satsumarx.com',
 'longBusinessSummary': 'Satsuma Pharmaceuticals, Inc., a clinical-stage '
                        'biopharmaceutical company, develops a novel '
                        'therapeutic product for the acute treatment of '
                        'migraine. Its lead product candidate is STS101, a '
                        'drug-device combination of a proprietary dry-powder '
                        'formulation of dihydroergotamine mesylate, which is '
                        'in Phase III clinical trials and can be '
                        'self-administered with a proprietary pre-filled, '
                        'single-use, and nasal delivery device. The company '
                        'was founded in 2016 and is headquartered in South San '
                        'Francisco, California.',
 'longName': 'Satsuma Pharmaceuticals, Inc.',
 'market': 'us_market',
 'marketCap': 445690304,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_414654964',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -37133000,
 'nextFiscalYearEnd': 1640908800,
 'open': 25.56,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '650 410 3200',
 'previousClose': 25.74,
 'priceHint': 2,
 'priceToBook': 3.6483984,
 'priceToSalesTrailing12Months': None,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 26.41,
 'regularMarketDayLow': 25.5,
 'regularMarketOpen': 25.56,
 'regularMarketPreviousClose': 25.74,
 'regularMarketPrice': 25.56,
 'regularMarketVolume': 14123,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 17387800,
 'sharesPercentSharesOut': 0.0089,
 'sharesShort': 155342,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 85416,
 'shortName': 'Satsuma Pharmaceuticals, Inc.',
 'shortPercentOfFloat': 0.023599999,
 'shortRatio': 1.45,
 'startDate': None,
 'state': 'CA',
 'strikePrice': None,
 'symbol': 'STSA',
 'threeYearAverageReturn': None,
 'toCurrency': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -11.201,
 'twoHundredDayAverage': 23.461008,
 'volume': 14123,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.satsumarx.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '94080'}